• <em>BRAF</em> mutation in myeloid neoplasm: incidences and clinical outcomes
• A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia
• A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML
• A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML
• A novel 3q interstitial deletion including GATA2 and ZNF148: A case report
• A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
• A primary pediatric acute myelomonocytic leukemia with t(3;21)(q26;q22): A case report
• Acute myelomonocytic leukemia and T-lymphoblastic lymphoma as simultaneous bilineage hematologic malignancy treated with decitabine: A case report
• Acute Myelomonocytic Leukemia Presenting as Fournier's Gangrene
• Acute onset of constrictive pericarditis due to acute myelomonocytic leukemia: A case and literature review
• AML with RUNX1::RUNX1T1 Cooperating two Mutations Relapsed Quickly after Achieving CR
• An unusual response to 5-azacitidine by a patient with chronic myelomonocytic leukemia
• Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies
• Application of the International Consensus Classification and World Health Organization 5th edition classification to a series of myeloid neoplasms
• ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides
• Azacitidine (Vidaza^®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)
• Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
• CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia
• CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment
• CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment
• Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants
• Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease
• Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis
• Chronic myeloproliferative neoplasm in adulthood in CBL syndrome harboring a splice-site <em>CBL</em> variant alongside a novel constitutional <em>CSF3R</em> variant
• Clinical Efficacy of Hypomethylating Agent Therapy in Patients with Chronic Myelomonocytic Leukemia
• Clinical, Histopathological and Molecular Spectrum of Cutaneous Lesions in Myelodysplastic Syndrome and Myeloproliferative Neoplasms (MDS/MPN): An Integrative Review
• Clinicopathologic Spectrum of Lysozyme-Associated Nephropathy
• Co-existing squamous cell carcinoma and chronic myelomonocytic leukemia with <em>ASXL1</em> and <em>EZH2</em> gene mutations: A case report
• Co-existing squamous cell carcinoma and chronic myelomonocytic leukemia with ASXL1 and EZH2 gene mutations: A case report
• Comprehensive analysis of the HCK gene in myeloid neoplasms: Insights into biological functions, prognosis, and response to antineoplastic agents
• Concurrent Langerhans cell histiocytosis and acute myeloid leukemia: A rare presentation of a rare case
• Core-binding factor abnormalities involving chromosome 16 in acute myeloid leukaemia: prognostic and therapeutic implications
• Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT
• CSF3R mutated myeloid neoplasms: Beyond chronic neutrophilic leukemia
• Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature
• Cytosine analogues as DNA methyltransferase substrates
• Dual-receptor T cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML
• Dysimmune manifestations associated with myelodysplastic neoplasms and chronic myelomonocytic leukaemias
• Early occurrence of acute myelomonocytic leukemia (M4/M5) after liver transplantation: a case report
• Enhanced Survival of Chronic Myelomonocytic Leukemia-Dysplastic over Proliferative Subtype after Allogeneic Hematopoietic Cell Transplant: A Tertiary Center Experience and Literature Review
• Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases
• Flow Cytometry Profiling of Plasmacytoid Dendritic Cell Neoplasms
• FLT3-ITD mutation-positive acute myeloid leukemia undergoing clonal transition with PTPN11 mutation at relapse
• Histamine dihydrochloride and low-dose interleukin-2 has antileukemic efficacy in NPM1-mutated and myelomonocytic/monocytic acute myeloid leukemia
• Identification of triciribine as a novel myeloid cell differentiation inducer
• Immunohistochemical differentiation of extramedullary acute myeloid leukemia from blastic plasmacytoid dendritic cell neoplasm
• Impact of <em>CSF3R</em> Mutation on Treatment Response and Survival of Patients with Acute Myeloid Leukemia
• Impact of CSF3R Mutation on Treatment Response and Survival of Patients with Acute Myeloid Leukemia
• Impact of immunosuppression intensified conditioning regimen for patients with strong positive pre-transplantation donor-specific anti-HLA antibodies (DSAs) undergoing haploidentical hematopoietic stem cell transplantation
• In vivo Targeting MEK and TNK2/SRC pathways in PTPN11 driven leukemia
• Infrequent Presentations of Chronic <em>NPM1</em>-Mutated Myeloid Neoplasms: Clinicopathological Features of Eight Cases from a Single Institution and Review of the Literature
• Integrated Clinical Genotype-phenotype Characteristics of STAT3-mutated Myeloid Neoplasms
• invariant Natural Killer T cell therapy as a novel therapeutic approach in hematological malignancies
• Iron overload promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of FOS
• Leukemia Cutis
• Leukemia Cutis-The Current View on Pathogenesis, Diagnosis, and Treatment
• Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients
• MDS/CMML from resource-limited region: Characteristics and comparison to tertiary reference European center
• Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities
• Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center
• Myeloid sarcoma incidentally found in lymph nodes dissected for advanced gastric cancer
• Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy
• Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study
• Natural history study of patients with familial platelet disorder with associated myeloid malignancy
• Natural History Study of Patients with Familial Platelet Disorder with Myeloid Malignancy
• No advantage of antimicrobial prophylaxis in AML/MDS/CMML patients treated with azacitidine-a prospective multicenter study by the Polish Adult Leukemia Group
• Observation and Management of Juvenile Myelomonocytic Leukemia and Noonan Syndrome-Associated Myeloproliferative Disorder: A Real-World Experience
• Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
• Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
• PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy
• Pediatric Hematopathology in the Era of Advanced Molecular Diagnostics: What We Know and How We Can Apply the Updated Classifications
• Periungual pyogenic granulomas after ravulizumab therapy in a child with acute myelomonocytic leukemia treated with hematopoietic stem cell transplant
• Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes
• Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes
• Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia
• Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia
• Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases
• Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms
• Prognostic Value of Pretreatment Fetal Hemoglobin Levels in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia Treated with Azacitidine: A Single-center Retrospective Study
• Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia
• Pyoderma gangrenosum complicated with hematological malignancies: Two case reports
• RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia
• Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
• Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
• Real-world study of the use of azacitidine in myelodysplasia in Australia
• Regulation of coagulation activation in newly diagnosed AML by the heme enzyme myeloperoxidase
• Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies
• RNA splicing dysregulation in hematological malignancies
• Severe Acute Kidney Injury Associated with Transformation of Chronic Myelomonocytic Leukemia into Acute Myeloid Leukemia: A Case Report
• Severe RAS-Associated Lymphoproliferative Disease Case with Increasing αβ Double-Negative T Cells with Atypical Features
• Spontaneous remission of choroidal involvement by chronic myelomonocytic leukemia: a case report
• Spontaneous remission without treatment of acute myelomonocytic leukemia associated with COVID-19 infection
• Targeting DNA methyltransferases for cancer therapy
• TFH lymphoma and associated clonal hematopoiesis
• The clinical features and prognostic implications of PTPN11 mutation in adult patients with acute myeloid leukemia in China
• The immutable relevance of myeloid sarcomas: Clinicopathological study of fourteen cases
• Unraveling trajectories from aplastic anemia to hematologic malignancies: genetic and molecular insights
• Unveiling the Tempest: Dermal Plasmacytoid Dendritic Cell Proliferation as the Harbinger of Acute Myeloid Leukemia
• Utility of KIT Mutations in Myeloid Neoplasms Without Documented Systemic Mastocytosis to Detect Hidden Mast Cells in Bone Marrow
• Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation